Clinical improvement

Hospitalization

Inflammatory/thromboembolic/infectious/metabolic markers

Radiological aspects

Viral infection

Adverse events

General improvement in clinicalsymptoms of COVID-19

Improvement of cough

Reduction of body temperature

Improvement of shortness of breath

Improvement of respiratory function

Improvement of oxygen saturation

Early weaning from oxygen support

Reduction in the need for invasivemechanical ventilation

Faster recovery from acute respiratorydistress syndrome (ARDS)

Prevention of clinical worsening

Reduction of mortality

Reduction of hospital stay

Reduction in the need for admission tothe intensive care unit (ICU)

Decrease in C-reactive protein

Reduction of ferritin

Decreased lactate dehydrogenase

Decreased fibrinogen

Decrease in interleukin 6

D-dimer decrease

Leukocyte normalization

Normalization of lymphocytes

Decrease in procalcitonin

Decreased Neutrophil-LymphocyteRatio

Normalization of alanineaminotransferase

Radiological improvement of lunglesions

Reduction of viral load

Faster RT-PCR negative

Presence

Absence

Unmentioned

Study

Name

Country

Therapy

Type of study

Number of hospitalized patients who received Ozone Therapy

Pneumonia severity level

A

Wu et al. (2020)*

China

GAHT, 40 mcg / ml, 100 ml, 1: 1, once a day on the first day and twice a day on the second to the fifth day, for 5 days, totaling 9 sessions

Report of a case

1

Severe

X

X

X¶

X

X

X

X

X

X

X

X

B

Zheng et al. (2020)*

China

GAHT, 20 mcg / ml, 100 ml, 1: 1, once a day for 7 days, totaling 7 sessions

Report of a case

2

Severe

X

X

X

X

X

X

X

X

C

Franzini et al. (2020)

Italy

Clinical trial

50

Moderate

X

X

X

X

X

X

X

X

X

X

X

D

Hernández et al. (2020)*

Spain

GAHT, 40 mcg / ml, 200 ml, 1: 1, 2 timer a day, for 3 days, totaling 6 sessions

Report of a case

3

Severe

X

X

X

X

X

X

X

X

X

X

X

E

Tascini et al. (2020)

Italy

GAHT, 40 mcg / ml, 200 ml, 1: 1, once a day, for 3 days, totaling 3 sessions

Cases and cortrols study

30

Mild to moderate

X

X

X

X

X

F

Hernández et al. (2021)

Spain

GAHT, 40 mcg / ml, 200 ml, 1: 1, 2 times a day for 5 days, totaling 10 sessions

Prospective case-control study

Severe

X

X

X

X

X

X

X

G

Fernández-Cuadros et al.(2020)*

Spain

IR, 35 mcg / ml, 100 ml, once a day for 5 to 10days, for a total of 5 to 10 sessions

Quasi-experimental prospective cohort study

Severe

X

X

X

X

X

X

X

X

XΔ

H

Pena-Lora et al. (2020)*

Spain

IR, 35 mcg / ml, 100 ml, once a day for 5 days, totaling 5 sessions

Report of a case

1

Severe

X

X

X

X

X

X

X

X

X

X

X

I

Shah et al. (2020)

India

1st) IR, 40 mcg / mL, 150mL, 2 times a day for9 days, totaling 18 sessions 2nd) PAHT 25mcg /mL, 5mL of O3 and 2 to 3 ml of blood, once aday for 9 days, totaling 9 sessions

Randomized clinical trial

30

Mild to moderate

X

X

X

X

X

X

X¤

X¤

X¤

X

X

J

Razzaq et al. (2020)*

Iraq

SFO3, 35-45mcg / mL, 500mL, 3 to 5 minutes of preparation in continuous bubbling, infusion in15 minutes, 1 to 2 times a day, for 5-10 days.

Clinical trial

104

Moderate to severe

X

X

X

X

K

Schwartz et al. (2020)

Spain

SFO3, 3-5mcg / mL, 200mL, 10 minutes of preparation in continuous bubbling, infusion of15 to 30 minutes, once a day, for 10 days.

Non-randomized clinical trial

35

Severe

X

X

X

X

X

X

X

X

X

X

X

X

X

J

Sharma et al. (2021)

India

SFO3. 5mcg / mL, 200mL, 20 minutes of preparation in continuous bubbling, infusion of 1hour, once a day, for 8 days.

Clinical trial

10

Moderate

X

X

X

X

X

X

X

X

X

X

X

X

X

XΦ

L

Hendawy et al. (2021)

Egypt

1) IR, 12.6 mcg / mL, 2 liters, two sessions2) IR, 12.6mcg/mL, 2 liters, one session

Report of a case

3

Mild and severe

X

X

X

X

X

X

X

Total Results

13

2

3

2

6

6

2

3

2

4

2

6

2

10

7

8

2

6

8

1

2

1

1

1

7

1

1

3

6

4

Note: * Studies without statistics; Δ Discreet weather, gas sensation; . Epistaxis associated with the use of heparin; ¤ Falling of inflammatory markers, without significant statistics; ¶ Improvement of refractory hypoxemia; Φ Mild pain at the injection site and headache.